# **HAAO Antibody (N-term) Blocking Peptide**

Synthetic peptide Catalog # BP9349a

### **Specification**

## HAAO Antibody (N-term) Blocking Peptide - Product Information

**Primary Accession** 

P46952

# HAAO Antibody (N-term) Blocking Peptide - Additional Information

**Gene ID 23498** 

### **Other Names**

 $3-hydroxyanthranilate\ 3,\ 4-dioxygenase\ \{ECO:0000255|HAMAP-Rule:MF_03019\},\ 113116\ \{ECO:0000255|HAMAP-Rule:MF_03019\},\ 3-hydroxyanthranilate\ oxygenase\ \{ECO:0000255|HAMAP-Rule:MF_03019\},\ 3-hydroxyanthranilic\ acid\ dioxygenase\ \{ECO:0000255|HAMAP-Rule:MF_03019\},\ HAD\ \{ECO:0000255|HAMAP-Rule:MF_03019\},\ HAAO\ \{ECO:0$ 

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

#### HAAO Antibody (N-term) Blocking Peptide - Protein Information

Name HAAO {ECO:0000255|HAMAP-Rule:MF\_03019, ECO:0000312|HGNC:HGNC:4796}

# **Function**

Catalyzes the oxidative ring opening of 3-hydroxyanthranilate to 2-amino-3-carboxymuconate semialdehyde, which spontaneously cyclizes to quinolinate.

### **Cellular Location**

Cytoplasm, cytosol.

# **HAAO Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

# • Blocking Peptides

### HAAO Antibody (N-term) Blocking Peptide - Images



## HAAO Antibody (N-term) Blocking Peptide - Background

HAAO is a monomeric cytosolic protein belonging to the family of intramolecular dioxygenases containing nonheme ferrous iron. It is widely distributed in peripheral organs, such as liver and kidney, and is also present in low amounts in the central nervous system. HAAO catalyzes the synthesis of quinolinic acid (QUIN) from 3-hydroxyanthranilic acid. QUIN is an excitotoxin whose toxicity is mediated by its ability to activate glutamate N-methyl-D-aspartate receptors. Increased cerebral levels of QUIN may participate in the pathogenesis of neurologic and inflammatory disorders. HAAO has been suggested to play a role in disorders associated with altered tissue levels of QUIN.

# **HAAO Antibody (N-term) Blocking Peptide - References**

Huang,Y.W. Gynecol. Oncol. 117 (2), 239-247 (2010)Huang,Y.W. Oncol. Rep. 22 (4), 853-861 (2009)Trynka,G. Gut 58 (8), 1078-1083 (2009)